13. The composition of claim 1, wherein said composition further comprises one or more of a non-ionic surfactant, a niosome, a polymer, a protein, and a carbohydrate. 

14. The composition of claim 10, wherein said lipid is modified to comprise a targeting agent selected from the group consisting of antibodies, mannose, folate, and trans› ferrin. 

15-21. ( canceled) 

22. A method of treating a disease in a subject, compris› ing: 

administering the composition of claim 1 to a subject diagnosed with a disease. 

23. The method of claim 22, wherein said administering reduces or eliminates symptoms of said disease. 

24. The method of claim 22, wherein said disease is an inflammatory disease. 

25. The method of claim 24, wherein said disease is acute or chronic. 

26. The method of claim 22, wherein said disease is selected from the group consisting of asthma, bronchiolitis, bronchiolitis obliterans, chronic obstructive pulmonary dis› ease (COPD), bronchitis, emphysema, hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, pneumoconio› sis, silicosis, meningitis, sepsis, malaria, rheumatoid osteoarthritis, psoriasis, acute respiratory disease syndrome, inflammatory bowel disease, multiple sclerosis, joint inflam› mation, reactive arthritis, hay fever, atherosclerosis, rheu› matoid arthritis, bursitis, gouty arthritis, osteoarthritis, poly› myalgia rheumatic arthritis, septic arthritis, infectious arthritis, asthma, autoimmune diseases, chronic inflamma› tion, chronic prostatitis, glomerulonephritis, nephritis, inflammatory bowel diseases, pelvic inflammatory disease, reperfusion injury, transplant rejection, vasculitis, myocardi› tis, colitis, appendicitis, peptic ulcer, gastric ulcer, duodenal ulcer, peritonitis, pancreatitis, ulcerative colitis, seudomem› branous colitis, acute colitis, ischemic colitis diverticulitis epiglottitis, achalasia, cholangitis, cholecystitits, hepatitis: Crohn’s disease, enteritis, Whipple’s disease, allergy, ana- 

phylactic shock, immune complex disease, organ ischemia, reperfusion injury, organ necrosis, hay fever, sepsis, septi› cemia, endotoxic shock, cachexia, hyperpyrexia, eosino› philic granuloma, granulomatosis, sarcoidosis, septic abor› tion, epididymitis, vaginitis, prostatitis, urethritis, bronchitis, emphysema, rhinitis, pneumonitits, pneumoult› ramicroscopic silicovolcanoconiosis, alvealitis, bronchioli› tis, pharyngitis, pleurisy, sinusitis, influenza, respiratory syncytial virus infection, HIV infection, hepatitis B virus infection, hepatitis C virus infection, herpes virus infection disseminated bacteremia, Dengue fever, candidiasis, malaria, filariasis, amebiasis, hydatidcysts, bums, dermati› tis, dermatomyositis, sunburn, urticaria, Warts, Wheals, vasulitis, angiitis, endocarditis, arteritis, atherosclerosis, thrombophlebitis, pericarditis, myocarditis, myocardial ischemia, periarteritis nodosa, rheumatic fever, Alzheimer’s disease, coeliac disease, congestive heart failure, adult respi› ratory distress syndrome, meningitis, encephalitis, multiple sclerosis, cerebral infarction, cerebral embolism, Guillame› Barre syndrome, neuritis, neuralgia, spinal cord injury, paralysis, uveitis, arthritides, arthralgias, osteomyelitis, fas› ciitis, Paget’s disease, gout, periodontal disease, rheumatoid arthritis, synovitis, myasthenia gravis, thyroiditis, systemic lupus erythematosis, Goodpasture’s syndrome, Behcet’s syndrome, allograft rejection, graft-versus-host disease, Type I diabetes, Type II diabetes, ankylosing spondylitis, Berger’s disease, Reiter’s syndrome, Hodgkin’s disease, ileus, hypertension, irritable bowel syndrome, myocardial infarction, sleeplessness, anxiety, local inflammation, and stent thrombosis. 

27. The method of claim 26, wherein said disease is caused by infection by a microorganism selected from the group consisting of Staphylococcus aureus, Streptococcus, Streptococcus pneumonia, Neisseria gonorrhoeae, Myca› bacterium tuberculosis, Borrelia burgdorferi, and Haemo› philus influenza. 

28-31. (canceled) 

* * * * * 

